Aim Immunotech Inc. · AMEX:AIM
Aim Immunotech — Investor Presentation (January 2026)
29 slides from Aim Immunotech's investor presentation, Jan 12, 2026
Slide 1: Corporate Presentation January 2026
NYSE American: AIM aimimmuno.com AIM ImmunoTech Corporate Presentation away 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements ie Qaim
Slide 3: Late-stage clinical immuno-pharma company
S AIM ImmunoTech We are a late-stage clinical immuno-pharma company focused on developing therapeutics across a number of disease areas, from immuno-oncology to immune disorders to viral diseases
Slide 4: Ampligen's Therapeutic Mechanism of Action
Ampligen’s Therapeutic Mechanism of Action 4 Qaim
Slide 5: Ampligen's Therapeutic Mechanism of Action
Ampligen’s Therapeutic Mechanism of Action oe Qaim
Slide 6: Ampligen's Excellent Safety Profile
Ampligen’s Excellent Safety Profilé oe Qaim
Slide 7: Ampligen's Excellent Safety Profile
Ampligen’s Excellent Safety Profilé a“ Qaim
Slide 8: Ampligen in Oncology
o AIM Ampligen in Oncology ae
Slide 9: Ensuring Effective Chemokine Modulation in Tumors is Important
Ensuring Effective Chemokine Modulation in Tumors is Important for Teff Cell Infiltration and Increased Survival Ampligen shown in clinical trials to increase CXCL10 and decrease CCL22 intratumorally with associated increase in the Teff/Treg ratio in subjects This helps explain Ampligen’s broad-spec
Slide 10: Primary Oncology Target: Late-Stage Pancreatic Cancer
Primary Oncology Target: Late-Stage Metastatic and Locally-Advanced Pancreatic Cancer Pancreatic Cancer Snapshot Pancreatic cancer is a highly unmet need that is expected to be the 2nd- leading cause of cancer deaths by 2030 10 Qaim
Slide 11: Pancreatic Cancer Intellectual Property Portfolio
Pancreatic Cancer Intellectual Property Portfolio Patent protection regarding pancreatic cancer and oncology development ¢ United States - Methods involve the administration of a unique synergistic combination of Ampligen and an anti-PD-L1 in the treatment of pancreatic cancer, renal cell carcinoma,
Slide 12: Foundation for Success in Pancreatic Cancer
Foundation for Success in Pancreatic Cancer Early Access Program (EAP) Indicated Statistically Significant Increased Overall Survival Compared to Historical Controls in the Treatment of Late-Stage Pancreatic Cancer Crt Erasmus University Medical Center Survival Data: Quality of Life: Qaim
Slide 13: Phase Metastatic Pancreatic Cancer Clinical Trial
Phase 2 Metastatic Pancreatic Cancer Glinical Trial 13 Qaim
Slide 14: DURIPANC - Mid-Year Results
DURIPANC - Mid-Year Re: Safety Toxicity - No grade 22 immune-related or systemic toxicities reported to date Efficacy Progression-Free Survival (PFS) - Among the 14 patients evaluable for progression-free survival, eight patients experienced disease progression within 6 months of treatment initiatio
Slide 15: Secondary Oncology Targets: Ovarian Cancer Clinical Trial
Secondary Oncology. Targets: Phase 2 Advanced Recurrent OvarianeGancegs Clinical Trial a5 Qaim
Slide 16: Advanced Recurrent Ovarian Cancer Clinical Trial - Results
Phase 2 Advanced Recurrent Ovarian Caneer Clinical Trial - Results 16 Qaim
Slide 17: Positive Data from Secondary Oncology Target
Positive Data from Secondary Oncology Target Indications Represent Significant Unmet Needs 19,880 287,850 | 151,030 99,780 New Cases Annually New Cases Annually New Cases Annually New Cases Annually 12,810 43,250 52,580 7,650 Deaths Annually Deaths Annually Deaths Annually Deaths Annually ClinicalTr
Slide 18: Ampligen in Immune System Disorders
o AIM Ampligen in Immune System Disorders 18 Qa
Slide 19: Post-COVID Condition Study (AMP-518)
Post-COVID Condition of Sponsor: AIM ImmunoTech Collaborators: AIM ImmunoTech and Amarex Clinical Research Study Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ampligen® in Patients With Post-COVID Conditions (AMP-518) (NCT05592418) Study Type: Pha
Slide 20: AMP-518 - Results
AMP-518 - Results ¢ The Ampligen group outperformed the placebo group in PROMIS® measures of fatigue in 12 of the 13 weeks tracked ¢ The Six-Minute Walk Test revealed a higher impact of Ampligen on distance traveled in six minutes at Week 13 compared to placebo ¢ Analysis of safety parameters demons
Slide 21: AMP-518 - Results
AMP-518 - Results Z Ampligen improves measures of fatigue over placebo, with portions of this data approaching statistical significance. Further, in-depth analysis of the complete study results is expected to allow the company to design future trials and calculate the study size necessary to achieve
Slide 22: AMP-516 Clinical Study
AMP-516 Clinical Study Positive results from our Phase 3 study of Ampligen forthe treatment of ME/CFS 51.2% @ Rintatolimod @ Placebo p=0.54" (A=4.8%) p=0.013" (A=15.9%) p=0.003' (A=33.6%) Percent of Patients 8 (n=41) (n=34) (n=59) (n=74) Responder Subset Non-Responder Subset (n=100) (n=108) ITT Popu
Slide 23: Ampligen as an Antiviral
o AIM Ampligen as an Antiviral ae Qa
Slide 24: Phase I Study of Intranasal Ampligen
AlM’s Phase 1 study Demonstr. Title: Safety, tolerability and biological activity of repeated intranasal administration of TLR3 agonist Ampligen (Poly I:Poly C12U) in healthy subjects Study Type: Phase | Safety Study of Intranasal Ampligen in Normal/Healthy Volunteers Protocol Summary: Randomized, d
Slide 25: Positive Antiviral Activity of Ampligen
Positive Antiviral Activity of Ampligén Intravenous and Intranasal Ampligen’s Potential as Prophylactic andsEarly-Onset Antiviral Therapies 25 Qaim
Slide 26: Our AIM Corporate Overview
Slide 27: Proven Management Team
Proven Management Team William Mitchell, MD, PhD Chairman of the Board of Directors Peter W. Rodino III, JD Chief Operating Officer, Executive Director for Governmental Relations, General Counsel, Secretary Christopher Nicodemus, MD Science Officer Qaim
Slide 28: Intellectual Property Portfolio - Market Exclusivity
Intellectual Property Portfolio - Market Exclusivity (ss) (39) Patents Pending Worldwide Applications 28 Sam
Slide 29: Unlocking the value of Ampligen
Unlocking the value of Ampligen with the priority goal of new drug approval in pancreatic cancer Unmet medical needs with little-to-no pipeline competition Consistent positive data from open-label, late-stage cancer clinical programs Big Pharma collaborators, including Merck Sharpe & Dohme and Astra
AIM ImmunoTech — Investor Presentation (January 2026) on 6ix